∆Ki67
HER2-ve tumours
In the control group for patients with HER2-ve tumours, there was a median fall of 14.6% (IQR: − 40.8–18.3) in Ki67 (∆Ki67In HER2 + ve patients, there was a median fall of 12.4% (IQR: − 31.7 to − 7.1) in Ki67; 5 patients (7.1%) had Ki67In order to understand this apparent, potentially artefactual change, analyses of change in Ki67 were explored according to type of sample from which Ki67